Clinical trial · Interventional
Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project analyzes the relationship between type 2 deiodinase gene polymorphism and the TSH inhibitory treatment efficacy in thyroid cancer patients with thyroidectomy, and explored the factors influencing TSH inhibitory treatment efficacy. It further explores whether patients with diO2-Thr92ALA genotype or DIO2 Orfa-Gly3ASP genotype should choose T4+T3 treatment, and the effect of different treatment options on the quality life of patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypothyroidism | — | UNRESOLVED | — |
| Thyroid Cancer, Papillary | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-T4 | Drug | — | UNRESOLVED |
| L-T4+T3 (thyroid tablet) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- L-T4 therapy group
- description
- Patients with refractory hypothyroidism still receive L-T4 therapy as usual.
- interventionNames
- Drug: L-T4
- type
- EXPERIMENTAL
- label
- L-T4+T3 therapy group
- description
- Patients with refractory hypothyroidism receive L-T4+T3 therapy
- interventionNames
- Drug: L-T4+T3 (thyroid tablet)
Primary outcomes (1)
- measure
- TSH suppression
- timeFrame
- Up to 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-65 2. Patients with Hypothyroidism after total thyroidectomy for papillary thyroid carcinoma 3. Patients were informed of the study and voluntarily willing to participate. Exclusion Criteria: 1. Having depression or other mental illness 2. Taking drugs that interfere with thyroid hormone absorption for other chronic diseases 3. impaired liver function, defined as aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN 4. impaired renal function ,eGFR: \<45 mL/min (calculated by MDRD formula) 5. Recent Cardiovascular Events in a patient: (1)Acute Coronary Syndrome (ACS) within 2 months prior to enrolment (2).Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment (3)Acute Stroke or TIA within two months prior to enrolment (4)Less than two months post coronary artery revascularization 6. Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure. 7\. Pregnant or breastfeeding women
References
Publications (0)
Data not yet available